Results 121 to 130 of about 14,494 (232)

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic

Microbial Biotechnology, Volume 19, Issue 2, February 2026.
Replication cycle of HIV‐1. The scheme provides an overview from virus entry over reverse transcription of viral RNA into viral DNA, provirus DNA integration into the host genome, genome expression by transcription and translation, proteolytic processing of the viral polyproteins, viral maturation to viral release from the cell. The various targets for
Harald Brüssow
wiley   +1 more source

2016 Pipeline Report HIV and TB [PDF]

, 2016
HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem, Lindsay McKenna, Mark Harrington, Mike Frick, Polly Clayden, Richard Jefferys, Simon Collins, Tim Horn   +7 more
core  

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA

Hepatology Research
Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir alafenamide fumarate (TAF) due to the ...
Shunsuke Yamada, Yoshihito Uchida, J. Kouyama, Kayoko Naiki, Shohei Tsuji, Hayato Uemura, Kayoko Sugawara, Nobuaki Nakayama, Y. Imai, T. Tomiya, Suguru Mizuno, Satoshi Mochida   +11 more
semanticscholar   +1 more source

How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
Pharmacological pitfalls and challenges in drug repurposing for emerging pathogens: lessons from COVID‐19. ABSTRACT The Covid‐19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS‐CoV‐2 but ...
Inès Ben Ghezala, Nathan Peiffer‐Smadja, Caroline Solas, Antoine Nougairède, Franck Touret, Marc Bardou   +5 more
wiley   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

The changing face of an epidemic: healthy old age with HIV [PDF]

, 2017
The demographics of the HIV epidemic in the UK have changed significantly. Owing to a steady rate of new diagnoses and improved survival, the population of individuals living with HIV continues to increase.
Chowdhury, M, Nugent, DB, Waters, LJ
core   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Journal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego, Laura Gragnani, Marcella Visentini, Riccardo Bomben, Luca Arcaini, Clodoveo Ferri, Valter Gattei, Cesare Mazzaro   +7 more
wiley   +1 more source

Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities

Journal of the International AIDS Society, Volume 29, Issue 1, January 2026.
Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage. Given price differentials between CAB‐LA and TDF/FTC, evaluating the cost‐effectiveness of potential PrEP coverage scenarios is warranted.
Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov   +11 more
wiley   +1 more source